Teacher Retirement System of Texas Sells 3,138 Shares of Dynavax Technologies Corporation (NASDAQ:DVAX)

Teacher Retirement System of Texas lowered its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 9.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,841 shares of the biopharmaceutical company’s stock after selling 3,138 shares during the period. Teacher Retirement System of Texas’ holdings in Dynavax Technologies were worth $413,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its holdings in Dynavax Technologies by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company’s stock worth $14,750,000 after acquiring an additional 32,347 shares during the period. Raymond James Financial Inc. purchased a new position in Dynavax Technologies during the fourth quarter worth about $192,000. Amundi boosted its holdings in shares of Dynavax Technologies by 172.6% in the 4th quarter. Amundi now owns 58,896 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 37,290 shares in the last quarter. Natixis Advisors LLC purchased a new position in shares of Dynavax Technologies in the 4th quarter worth about $288,000. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at about $131,000. Institutional investors own 96.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wall Street Zen lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 6th. The Goldman Sachs Group reduced their price objective on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research report on Thursday, April 17th. Finally, JMP Securities reduced their price objective on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $24.00.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $10.67 on Friday. The business’s fifty day simple moving average is $10.08 and its 200-day simple moving average is $11.73. The company has a market cap of $1.28 billion, a PE ratio of -20.52 and a beta of 1.03. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. Dynavax Technologies Corporation has a 12-month low of $9.22 and a 12-month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. The firm had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.